Navigation Links
ADVENTRX Completes Acquisition of SynthRx
Date:4/11/2011

SAN DIEGO, April 11, 2011 /PRNewswire/ -- ADVENTRX Pharmaceuticals, Inc. (NYSE Amex: ANX) today announced that it has completed its acquisition of SynthRx, Inc., now a wholly owned subsidiary of ADVENTRX.  SynthRx's lead product candidate is a novel, proprietary, rheologic and antithrombotic compound, poloxamer 188, that ADVENTRX will develop as ANX-188.

"With ANX-188, we add to our pipeline another late-stage asset with multiple exciting development opportunities.  We plan to meet with FDA this year to reach agreement on a protocol for a pivotal phase 3 study for treatment of sickle cell crisis in a pediatric population, an orphan indication," said Brian M. Culley, Chief Executive Officer of ADVENTRX.  "Because sickle cell crisis is a severe and painful condition often with life-threatening complications and for which existing drugs provide only limited symptomatic relief, there is a significant need to improve treatment options.  Beyond sickle cell, ANX-188 may have clinical utility in other acute events related to microvascular-flow abnormalities, such as heart attack, stroke and hemorrhagic shock."

As previously announced, ADVENTRX and SynthRx entered into a definitive merger agreement in February 2011, which was completed on April 8, 2011.  In connection with the closing, ADVENTRX issued approximately 2.8 million shares of its common stock, of which 862,078 shares (or an approximately 3.3% ownership stake) are vested and approximately 1.9 million are unvested.  The unvested shares will vest upon dosing of the first patient in a phase 3 clinical study meeting certain criteria, subject to reductions based on the timing of dosing of the first patient and the anticipated size of the study. SynthRx stockholders also are entitled to receive additional shares of common stock upon successful achievement of development milestones consisting o
'/>"/>

SOURCE ADVENTRX Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. ADVENTRX Announces Fast Track Designation Granted By the FDA For CoFactor For the Treatment of Metastatic Colorectal Cancer
2. ADVENTRX Announces Completion of Patient Enrollment in ANX-530 Marketing-Enabling Clinical Study
3. ADVENTRX Meets Primary Endpoint in ANX-530 Marketing-Enabling Clinical Study
4. ADVENTRX Announces Completion of Patient Enrollment in Phase 2 Clinical Trial of CoFactor(R) for the Treatment of Advanced Breast Cancer
5. ADVENTRX to Present ANX-201 Preclinical Data at Keystone Symposia HIV Pathogenesis Conference
6. ADVENTRX to Present CoFactor Phase 2 Breast Cancer Data at the 2008 Annual Meeting of the American Society of Clinical Oncology (ASCO)
7. ADVENTRX Announces ANX-530 Safety Data From Registrational Bioequivalence Clinical Study
8. ADVENTRX Presents CoFactor Data at the 2008 Annual Meeting of the American Society of Clinical Oncology (ASCO)
9. ADVENTRX Announces CoFactor(R) Phase 2b Clinical Trial Overall Survival Results
10. ADVENTRX Announces Preliminary Response Rate Data From Discontinued Phase 3 Trial of CoFactor(R)
11. ADVENTRX Completes Patient Enrollment in ANX-514 Bioequivalence Study
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/30/2014)... 2014 WuXi PharmaTech (Cayman) Inc. (NYSE: ... platform company serving the pharmaceutical, biotechnology, and medical device ... and the United States , today ... Tel Aviv area of Israel.  ... broad platform of integrated R&D services to local customers. ...
(Date:10/30/2014)... Boston Scientific Corporation (NYSE: BSX ... Suisse Annual Healthcare Conference on Tuesday, November 11, 2014 ... Brennan , executive vice president and chief financial officer, ... approximately 8:00 a.m. PT followed by a question and ... presentation and question and answer session will be available ...
(Date:10/30/2014)... , Oct. 30, 2014   ViaDerma, Inc. ... to bringing new products to market, has recently ... TetraStem. TetraStem is a topical liquid tetracycline-based antibiotic ... that can convert oral medication active ingredients into ... a first aid antibiotic to help prevent skin ...
Breaking Medicine Technology:WuXi AppTec Launches Representative Office in Israel, Forms Strategic Collaboration with Pontifax 2Boston Scientific To Participate In 2014 Credit Suisse Annual Healthcare Conference 2ViaDerma, Inc. Lead Product TetraStem Shown Effective in Fighting Staph Infections including MRSA 2ViaDerma, Inc. Lead Product TetraStem Shown Effective in Fighting Staph Infections including MRSA 3
... , FRAZER, Pa., ... announced that it has filed a lawsuit in U.S. District ... of U.S. Patent Nos. 7,132,570 (the ",570 Patent"), 7,297,346 (the ... product NUVIGIL® (armodafinil) Tablets [C-IV]. Cephalon has a three-year ...
... , NEW ... market research report is available in its catalogue: , ... , http://www.reportlinker.com/p0164248/Pharmaceutical-Contract-Manufacturing---Global-Market-Trends.html ... form of increasing competition in generic markets, rising cost ...
Cached Medicine Technology:Cephalon Files Patent Infringement Lawsuit Against Teva Pharmaceuticals 2Cephalon Files Patent Infringement Lawsuit Against Teva Pharmaceuticals 3Cephalon Files Patent Infringement Lawsuit Against Teva Pharmaceuticals 4Reportlinker Adds Pharmaceutical Contract Manufacturing - Global Market Trends 2Reportlinker Adds Pharmaceutical Contract Manufacturing - Global Market Trends 3Reportlinker Adds Pharmaceutical Contract Manufacturing - Global Market Trends 4Reportlinker Adds Pharmaceutical Contract Manufacturing - Global Market Trends 5
(Date:10/30/2014)... Graphics, coding, typography and search engine optimization– ... of web design and require thorough knowledge to create ... to create a website can be as easy as ... reviews and Facebook posts all accumulate on a multiple ... evolution of how a business can develop a website," ...
(Date:10/30/2014)... 30, 2014 High efficacy and ... in the medical-grade skin care domain: Cosmederm, the ... uniquely potent topical dermatological products, today announces the ... ) with patented COSMEDERM®-7 anti-irritant technology. , ... (50% and 70%) and a low pH (pH ...
(Date:10/30/2014)... October 30, 2014 PreDiabetes Centers ... PreD Store shoppers with a supply of sugardown®, ... to reduce post-meal blood sugar spikes. Learning how to ... an important part of a diabetes prevention plan. , ... receive one complimentary tube of sugardown. The offer expires ...
(Date:10/30/2014)... (PRWEB) October 30, 2014 Radio listeners ... raising questions about the impact of traditional radio commercials ... method most likely to influence a purchasing decision. , ... of 525 consumers conducted by radio marketing company CRN ... categories, isolating the results of respondents who indicated they ...
(Date:10/30/2014)... Tara Haelle HealthDay Reporter ... More than 100 genes have been identified that appear ... And researchers say they are on their way ... contribute to the disorder. Autism spectrum disorders include ... social difficulties and repetitive behaviors. An estimated one in ...
Breaking Medicine News(10 mins):Health News:Facebook Websites In Thirty-Seconds 2Health News:Cosmederm Redefines Peel Science Standard with Launch of Refinity® Skin Health System 2Health News:Cosmederm Redefines Peel Science Standard with Launch of Refinity® Skin Health System 3Health News:Cosmederm Redefines Peel Science Standard with Launch of Refinity® Skin Health System 4Health News:PreDiabetes Treatment Company Offers PreD Store Shoppers Supplements to Support Healthy Blood Sugar 2Health News:CRN Research On Radio Messaging Effectiveness Now Available In Four Specific Product Categories 2Health News:CRN Research On Radio Messaging Effectiveness Now Available In Four Specific Product Categories 3Health News:Discovery of 100-Plus Genes Tied to Autism May Improve Treatments 2Health News:Discovery of 100-Plus Genes Tied to Autism May Improve Treatments 3
... Study highlights:, - A blood test recently approved ... better than tests currently used in the,United States., ... mortality in these,patients, which should allow healthcare providers to ... NEW ORLEANS, Nov. 11 A new blood test,identifies ...
... NEW ORLEANS, Nov. 11 A veteran ... Association Howard L.,Lewis Achievement Award for excellence ... Stiles of Freemont, Calif., was honored for ... clinical, economic,political, ethical and cultural implications of ...
... BROOK, Ill., Nov. 11 Over $3.2 million ... days by members of the University,HealthSystem Consortium,s (UHC) ... tool. With the new, easy-to-use UHC,Interactive WorkPlan, materials ... the intuitive reports to identify, analyze, and act ...
... (NEWARK, N.J., Nov. 11, 2008) The F.M. Kirby Foundation ... of Nursing at Rutgers, The State University of New Jersey, ... New Jersey residents. , The grant will also fund the ... research and service in the best academic tradition, said Interim ...
... the treatment of erectile dysfunction and pulmonary hypertension ... of the type-5 phosphodiesterase. The type-5 phosphodiesterase is ... of sildenafil on splanchnic blood flow and portal ... led by Otto Clemmesen from Denmark addresses this ...
... Nov. 11 /PRNewswire-FirstCall/ - SXC Health Solutions Corp.,("SXC" ... SXC), a leading provider of,pharmacy benefits management services, ... the Yale Club in New York City on ... 8:00 a.m. until approximately,11:00 a.m. eastern time and ...
Cached Medicine News:Health News:New Blood Test Better Identifies Heart Failure Patients in ER 2Health News:New Blood Test Better Identifies Heart Failure Patients in ER 3Health News:New Blood Test Better Identifies Heart Failure Patients in ER 4Health News:SpendLINK(TM) Enhancements Help Academic Medical Centers Easily Track Savings Opportunities 2Health News:SXC Health Solutions to host analyst and institutional investor event 2
... is enzyme immunoassay kit for the ... concentration in serum. Enzyme immunoassay (EIA) ... many protein hormones in body fluids ... rapid and specific assay. This enzyme ...
SHIONORIA BNP,is a reagent used in the measurement of blood BNP. The blood BNP test allows accurate estimation of coronary functions....
... method for the semi-quantitative determination of ... human serum. The results of the ... an aid in the diagnosis of ... with elevated anti-neutrophil cytoplasmic antibodies (P-ANCA) ...
... The determination of Ang ... in monitoring the pharmacological effect ... variety of angiotensin converting enzyme ... II receptor antagonists as well ...
Medicine Products: